Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01004 Ointment in Adults with Mild to Moderate Atopic Dermatitis
NCT06553287Phase 1Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LNK01004 in atopic dermatitis (AD) (4 arms), sponsored by Lynk Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at Week 4. Started Jul 2023; status: completed.
02
Drugs
LNK01004
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06553287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553287.